| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Wednesday, October 19, 2022 1:08:17 PM
You can’t actually have 5 year survivors running a trial like that for just 5 years, or even 6 years. Patients are enrolled over time. Besides, OS was secondary. PFS was primary, and the company says itself, the trial was stopped prematurely, on an interim review of data. Period. Full stop.
The 5 year rate was statistically predicted, based on PFS.
And PFS results can be influenced by pseudoresponse.
More importantly, there is no known mechanism by which it kills tumor cells. It is claimed it has no impact on normal tissue and SLOWS tumor tissue growth. It is therefore hard to imagine anyone being free from paying $21,000 per month forever. That is an outrageous cost for a palliative treatment.
Like I said, should be made available. But I understand why systems limit it, because it is highway robbery. There is no reason it should cost so much forever. None. That is re Optune, by Novocure, just to be clear.
The 5 year rate was statistically predicted, based on PFS.
And PFS results can be influenced by pseudoresponse.
More importantly, there is no known mechanism by which it kills tumor cells. It is claimed it has no impact on normal tissue and SLOWS tumor tissue growth. It is therefore hard to imagine anyone being free from paying $21,000 per month forever. That is an outrageous cost for a palliative treatment.
Like I said, should be made available. But I understand why systems limit it, because it is highway robbery. There is no reason it should cost so much forever. None. That is re Optune, by Novocure, just to be clear.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
